| P2093 | author name string | M Kudo | |
| P2860 | cites work | Sorafenib in advanced hepatocellular carcinoma | Q27861075 |
| | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 |
| | Chemoembolization in patients with hepatocellular carcinoma | Q38155505 |
| | Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy | Q38155506 |
| | Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | Q45980006 |
| | Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma | Q57214428 |
| | Effect of vitamin K2 on the recurrence of hepatocellular carcinoma | Q57763211 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 59-60 | |
| P577 | publication date | 2012-09-01 | |
| P1433 | published in | Liver cancer | Q26842090 |
| P1476 | title | Why does every hepatocellular carcinoma clinical trial using molecular targeted agents fail? | |
| P478 | volume | 1 | |